Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2001, for AVI BioPharma, Inc. (Note: The request metadata listed "Sarepta Therapeutics," but the filing text explicitly identifies the registrant as AVI BioPharma, Inc.). The company is classified as a "Development Stage Company" that has been unprofitable since its inception in July 1980. Its primary activities involve research and development (R&D) for biopharmaceutical technologies, with no material product revenues expected for at least the next 12 months.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2001 | Nine Months Ended Sep 30, 2001 | As of Sep 30, 2001 |
|---|---|---|---|
| Revenues | $307,549 | $410,793 | N/A |
| Net Loss | $(15,596,194) | $(22,320,919) | N/A |
| Net Loss Per Share | $(0.67) | $(1.01) | N/A |
| Cash and Cash Equivalents | N/A | N/A | $24,612,518 |
| Total Assets | N/A | N/A | $33,140,200 |
| Accumulated Deficit | N/A | N/A | $(82,614,752) |
| Operating Expenses | $3,652,594 | $11,081,534 | N/A |
Debt and Liquidity: The company reported no long-term debt. Current liabilities totaled $1,581,630. Liquidity is supported by cash balances and short-term securities (available-for-sale) valued at $3,157,173.
Material Changes vs. Prior Period
- Significant Non-Cash Write-Down: The most material change was a one-time, non-cash write-down of $12,523,088 on short-term securities (SuperGen, Inc. common stock) due to an "other than temporary impairment." This charge drove the net loss for the quarter to $(15.6M) compared to $(2.3M) in the same period of 2000.
- Revenue Decline: Revenues for the nine months ended September 30, 2001, decreased to $410,793 from $1,272,338 in the prior year, primarily due to the absence of a $1,000,000 license fee received in Q1 2000.
- Expense Growth: Operating expenses increased by approximately 37% for the nine-month period (from $8.1M to $11.1M) due to increased R&D staffing, regulatory affairs, and clinical testing costs.
- Cash Position: Cash and cash equivalents decreased by $1.3 million from the beginning of the year, driven by operating cash outflows of $9.2M and investing outflows of $2.7M, partially offset by $10.6M in financing proceeds.
Outlook, Risks, and Management Commentary
- Outlook: Management expects to continue incurring losses for the foreseeable future. Cash resources are projected to satisfy requirements for approximately twenty-four months. The company may need to raise additional capital through public or private offerings if significant product revenues or partnerships do not materialize.
- Facilities: The company has substantially completed its GMP manufacturing facility and is commencing testing and validation, with manufacturing for clinical trials expected to begin in mid-2002.
- Risks: Key risks include the ability to generate product revenues, achieve profitability, and secure regulatory approvals. There is no assurance that the company will ever achieve profitability.
- Unusual Items: The $12.5M write-down of SuperGen securities was a non-cash event that significantly impacted the reported net loss but did not affect cash flow from operations.
Investor Verification Checklist
- Identity Confirmation: Verify that the filing is for AVI BioPharma, Inc., not Sarepta Therapeutics, as the metadata request may have contained an error.
- Impact of Write-Down: Confirm the nature of the $12.5M impairment charge on SuperGen securities and its classification as a non-cash item.
- Burn Rate: Assess the sustainability of the current cash balance ($24.6M) against the stated 24-month runway and increasing R&D expenditures.
- Revenue Sources: Review the dependency on license fees and grants, noting the significant drop in revenue compared to the prior year.
- Dilution Risk: Monitor potential future capital raises, as the company explicitly states it may need to issue additional securities, which could be dilutive.